Real-World check: how well does the RSV shot protect seniors?
NCT ID NCT06077968
Summary
This study aims to understand how effective the ABRYSVO vaccine is at preventing severe RSV infections in real-world settings. Researchers will analyze existing health records of adults aged 60 and older to see if the vaccine reduces hospitalizations and emergency visits related to RSV. The study will also look at how long protection lasts and the potential benefit of a booster shot.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RESPIRATORY SYNCYTIAL VIRUSES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Pfizer
New York, New York, 10001, United States
Conditions
Explore the condition pages connected to this study.